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Progesterone
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Abstract
The Women’s Health Initiative issues, confusions, and misunderstandings 
regarding women’s and medical staff ’s fears about coronary heart disease; 
stroke; venous thromboembolism; breast cancer; metabolic, cognitive and 
mood disorders; and general mortality have driven many attempts to promote 
other safe regimens for perimenopause/early menopause and midlife health. 
Perimenopause/early menopause climacteric syndrome may be safely treated 
with sequential transdermal/percutaneous estrogens and progestogens/vaginal 
progesterone or continuous transdermal estrogen plus intrauterine system 
medicated with progestogen/progesterone or with continuous combined trans-
dermal estrogen-vaginal progesterone regimen, when menopause since 3 years. 
Endometrial safety is assessed in terms of endometrial hyperplasia and carcinoma 
prevention. Transvaginal sonography, hysteroscopy, and endometrial biopsy at 
6/12 months ensure about secretory and atrophy/inactive endometrial aspects as 
markers for endometrial safety. The majority of endometrial carcinomas depicted 
after MHT are high grade, not estrogen dependent, developed on an atrophic 
endometrium. The histologic, genomic, and transcriptomic assessments with 
immunohistochemistry are diagnoses adjunct for cell proliferation/mitosis and 
apoptosis presence. Proteins, growth factors, cytokines as PAX2, PTEN and its 
genetic aberrations, microRNA-binding protein family (IMP, IGF-BP, progester-
one dependent), bcl 2, Ki-67, K-ras, p53, p16, and steroid (estrogen and proges-
terone) receptors are markers for differentiation between benign hyperplasia/
endometrial intraepithelial neoplasia, type 1/type 2 endometrial carcinomas, and 
long-term outcome.
Keywords: non-oral routes, hormone therapy, perimenopause, menopause, 
endometrial hyperplasia, endometrial carcinoma
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1.  Introduction: update on the importance of the hormone treatment in 
perimenopausal women—non-oral routes of hormone therapy
The menopausal transition is associated with profound dynamic and critical 
changes of the reproductive tract, and in the hypothalamic-pituitary-ovarian 
axis, which have been well chronicled and matched with concomitant symptoms 
regarding the characteristics of menstrual cycle—the most important parameter 
in the new criteria of STRAW +10 (2012), which starts with the irregularities 
from stage-3b/-3a in the late reproductive age [1, 2], and of all other organs and 
tissues of the women’s body, biology and psychology through this time of life. 
There are ethnic differences in symptoms and hormones that may reflect either 
basic biologic variations in hormone receptors and actions or the different 
social milieus that women in different ethnic groups experience [3]. The highly 
prevalent menopausal symptoms are sufficiently bothersome to drive almost 
90% of women to seek out their healthcare provider for advice on how to cope 
with it. Current medical management of perimenopause should include screen-
ing for general health maintenance, avoidance of weight gain—a very impor-
tant parameter for endometrial health—and a holistic approach to symptoms 
(Figure 1).
Menopausal hormone therapy (MHT) is indicated for the treatment of vasomo-
tor symptoms and menopausal genitourinary syndrome caused by hypoestrogen-
ism. MHT helps in the prevention of osteoporosis, colorectal cancer, type 2 diabetes 
mellitus, and possibly coronary heart disease (CHD), and Alzheimer’s disease if 
started early in the perimenopause or early postmenopause—+1a/+1b (STRAW 
+10) in the “window of opportunity,” with a positive effect on quality of life and 
reduction of global mortality.
The initial and quick publication of the results of Women’s Health Initiative 
(WHI) (2002) led to confusion and fear regarding medical recommendations and 
women’s use of MHT in conjunction with CHD, stroke, and venous thromboembo-
lism, metabolic disorders, breast cancer, cognitive and mood disorders, and general 
Figure 1. 
The stages of reproductive aging workshop +10 staging system for reproductive aging in women (adapted from 
Ref. [1]).
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mortality [4]. The analyze of risks of endometrial and colon cancer proved their 
reduction by MHT in postmenopausal women, being proven by the reduction of 
colon cancer by HT in postmenopausal women.
Timing of therapy is time since menopause, being more important than 
women’s age. When the benefits are higher than risks, as was proven by previous 
observational studies, animal models, and new RCT—as Kronos Early Estrogen 
Prevention Study, Early Versus Late Intervention Trial With Estradiol, Estrogen 
and Thromboembolism Risk, at near 10 years from the premature closure of both 
arms of WHI (2002, 2004), when on recorded the “end of an era”. The personalized 
recommendations of MHT, or tailoring the use of MHT to appropriate candidates, 
with the ultimate goal of developing a personalized risk/benefit prediction model 
must take into account clinical and genetic factors, “patient-centered” outcomes as 
sense of well-being, and/or quality of life.
1.1  Non-oral versus oral route for hormone therapy administration: advantages 
and disadvantages
Oral HT was and still may be the most commonly used route of administration in 
the USA and all over the world. Evidence suggests that oral delivery may lead to some 
undesirable physiologic effects caused by significant gut and hepatic metabolism.
After closure of the estro-progestogen arm of the WHI (2002), some researchers 
admitted that not all estrogens and progestogens are alike, and alternative drugs, 
doses, and delivery systems may exhibit better safety profiles than CEE/MPA (with 
co-multiple and complex studies of the WHI), with no loss of efficacy [5, 6]. The 
next subchapters will present the transdermal/percutaneous route for estrogens, 
the vaginal route for micronized progesterone, and the intrauterine systems with 
levonorgestrel/progesterone for recommendation in menopause transition—early 
and late perimenopause and early postmenopause from the road of menopause [2]. 
The best regimen, formula, and dosage—the lowest efficient estrogen dose—will 
give the opportunity to medical staff to stratify the individual risks and to personal-
ize the MHT indications [7].
1.1.1 Transdermal/percutaneous and nasal routes for estrogens
Transdermal/percutaneous drug delivery may mitigate some of the undesirable 
physiologic effects caused by significant gut and hepatic metabolism of oral HT, 
which still may be the most commonly used route of administration for MHT in the 
USA and many other countries. Active systems deliver therapeutics noninvasively 
across intact skin by means of an electric potential (electrotransport) [8], ensur-
ing rapid onset and termination of action, self-administration, and attainment 
of therapeutic hormone levels with low daily doses, with the disadvantage of the 
variable intra- and interindividual percutaneous absorption and skin irritation in 
some patients, when women use patches.
The used estrogen is 17-β-estradiol, and women from European countries 
(Austria, Belgium, France, Germany, Italy, Romania, Spain, Switzerland, the 
Netherland, and the UK), and Canada used it during the twentieth century’s last 
decade. It is available in multiple formulations—matrix, patches (25, 50 μg/day), 
and non-patches, as topical gel (hydroalcoholic gel containing 0.06% or 0.1% 
17β-E2), spray, emulsion, and lotion [9] and recently in the technology of micellar 
nanoparticles with their unique physical and chemical properties which enable 
transport of substances directly into the skin [10, 11].
The pharmacokinetic and pharmacodynamic differences between oral  
and non-oral routes of administration give to medical staff new therapeutic 
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perspectives for fewer health risks than oral therapy with estrogen, because only 
systemic therapy controls the moderate and severe climacteric syndrome, and 
associated to these data on must remember the large interindividual variability in 
the pharmacokinetics of estrogens. A dose-dependent effect explains why higher 
dose, longer duration, and residual endogenous estrogens are known risk factors 
to develop endometrial lesions and uterine bleeding with estrogens, and according 
to this pharmacokinetic condition, and to ovarian aging and continuous synthesis 
of endogenous estrogens, the actual recommendation is to use the lowest estrogen 
dose. The oral estrogens are converted to estrone (E1), and its conjugates, with less 
estrogenic activity than estradiol (E2), and the extensive metabolism of oral estro-
gens is inducing a higher ratio of E1 to E2 in the blood stream, which is opposite to 
the physiological levels in premenopausal women [12], and the formation of other 
metabolites from conjugated equine estrogens (CEE) used in the WHI was demon-
strated to be antiestrogenic or may have unrecognized pharmacologic activity in the 
human body [13].
The transdermal/percutaneous and nasal administration of 17β E2 avoid the 
first-pass liver metabolism and the significant hepatic stimulation, without supra-
physiologic concentrations in the liver. E2 is delivered directly, unmetabolized in the 
systemic circulation, and the estrogen doses are reduced in comparison to the oral 
formulation, maintaining a similar E2/E1 ratio to that of premenopausal women, by 
avoidance of gut and liver metabolism. Another peculiarity of transdermal/percuta-
neous route is the constant blood level of estrogens, without the peaks and troughs 
inherent to oral estrogens [14]. This quality is providing a more consistent blood 
level for the control of vasomotor symptoms and sleep disorders in perimenopause 
[15]. The lowest effective dose which covers treatment goals was considered to be 
0.014–0.0375 mg transdermal/percutaneous 17β E2 patch, and 50 μg/day was the 
assessed dose in the majority of studies for sequential/cyclic regimens and 25 μg/day 
for continuous combined regimens.
The newest application method is the estradiol metered-dose transdermal 
spray (EMDTS) [16], which was proven to ensure a precise dosing, with the 
maximum of E2 concentration at 18–20 h after application (1 or 2 or 3 puffs), 
and a stable level of estradiol, estrone, and estrone sulfate on the 7th–8th day of 
application.
Lower HT doses generally have fewer side effects, as breast tenderness and 
uterine bleeding, and may have a more favorable benefit-risk ratio than standard 
doses [17]. The UK General Practice Research Database for a nested case-control 
study showed that the risk of stroke did not increased with low-dose transdermal 
estrogen (≤0.05 mg/day), but increased with oral therapies and higher transdermal 
doses [18]. The systemic benefits of transdermal estrogens are connected to their 
bioavailability and metabolic peculiarities—less pronounced effects on hepatic 
protein synthesis, such as markers of inflammation, coagulation, and fibrinolysis, 
to lower or no risk of deep vein thrombosis [19], stroke [20], and myocardial infarc-
tion, even in thrombophilic patients [21], and lower or no effects on steroid-binding 
proteins, but more favorable effects on triglycerides [22].
One recent, large observational cohort study of postmenopausal women (45, 112 
cases hormone treated, with a mean duration of 5.5 years of HT use) made a mul-
tiple statistic comparison of clinical outcomes among users of oral and transdermal 
estrogen (CEE or E2) therapy, with or without progestogen, in the Women’s Health 
Initiative Observational Study on Menopause [23], and confirmed all the benefits 
of non-oral estrogens and their beneficial effect on the global index events (GIE) 
(defined as the time to the earliest of CHD, invasive breast cancer, stroke, pulmo-
nary embolism, colorectal cancer, endometrial cancer, hip fracture, and death from 
any cause) and stratified the results by duration of HT usage (mean 5.5 years), 
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age at time of HT initiation (<60 years, 60–69 years, and ≥ 70 years), years since 
menopause, body mass index (BMI), and ethnicity.
The fear of breast cancer is counterbalanced by transdermal estrogens and 
vaginal micronized progesterone, a fact demonstrated by the figures of the large 
observational French study E3N Cohort, which showed a small increase in the risk 
of breast cancer (HR: 1.31; 95% CI: 1.15–1.48), after 5 years of use, but the risk was 
no longer statistically significant following discontinuation of MHT (HR: 1.15; 95% 
CI: 0.93–1.42) [24].
1.1.2 Low-dose vaginal estrogens
Low-dose vaginal estrogen preparations as cream, suppositories, and pessaries 
are recommended for long-term use in symptomatic women as required, and all 
topical estrogen preparations have been shown to be effective in this context. There 
is no requirement to combine them with systemic progestogen treatment for endo-
metrial protection, as low-dose or ultralow-dose (10 μg vaginal 17β-estradiol tablets) 
[25, 26] estrogen preparations do not result in significant systemic absorption, and 
the risk of endometrial hyperplasia and cancer is low. After 52 weeks of such treat-
ment, a case with hyperplasia without atypia and a case with endometrial adenocar-
cinoma was discovered, which was considered to be previous to the 17β-E2 vaginal 
treatment [25]. When the estrogen is estriol—a weak estrogen, with low potency to 
the estrogen nuclear receptor—the endometrial and breasts’ risks are null [27].
The British Menopause Society considers that it is safe to recommend only 1-year 
use of vaginal estrogens, and the clinicians are advised to use the lowest effective 
dose for symptoms’ control and to counsel women regarding this [28, 29]. A vaginal 
ring that delivers a large dose of estrogen to the whole body may be an option for 
HT in hysterectomized women; vaginal rings more often deliver low doses and are 
considered topical therapy.
1.1.3 Vaginal versus oral route for progesterone
The addition of a progestin (progesterone/progestogen) has only one indication: 
endometrial protection and endometrial safety during MHT—the prevention of 
hyperplasia and cancer. Progesterone, the native hormone produced by the corpus 
luteum during the luteal phase of the menstrual cycle, is the unique option when 
one seeks “physiological” hormone replacement therapy. The pure progesterone was 
synthesized in large amount from the plant diosgenin by the chemist Russell Marker in 
1940 [30]. Depending on its chemical structure, a progestogen can either enhance (e.g. 
hot flushes, gonadotropin release, breast epithelial proliferation, and bone mineral 
density) or antagonize (e.g. endometrium, arterial wall, lipid metabolism, hepatic pro-
tein synthesis, and mood) the effects of the estrogen component [31]. Progesterone/
progestogens have gene effects on estrogen receptors’ synthesis downregulation and 
metabolic effects on rising levels of the enzyme 17-hydroxysteroid dehydrogenase, 
which transforms E2 to E1—sulfate, a weak estrogen—and these effects mean the 
arrest of endometrial glandular cell proliferation, cell differentiation, and secretory 
activity, and stroma decidualization. Actually, it is very well known that progestins 
protect the endometrium by inducing secretory transformation within the endometrial 
glands and stroma decidualization, and their capacity to restore to the normal endo-
metrium without signs of differentiation or secretion is assessed after minimum 6 days 
and daily administration for 3–6 months in the conditions of hyperplasia [32]. These 
facts were assessed regarding oral compounds such as MPA, levonorgestrel, and nor-
ethisterone during the last two decades of the twentieth century, and less with vaginal/
transdermal route of administration. Hyperplasia was reverted by the administration 
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of MPA continuously for 6 weeks or cyclically for 3 months (2 weeks per month), these 
being the two regimens most widely used during the years 1990–2000 [33].
Available progestins—progesterone/progestogens—differ largely in their hor-
monal pattern, and, in addition to their progestogenic and antiestrogenic actions on 
the endometrium, they can exert androgenic, antiandrogenic, glucocorticoid, and/
or anti-mineralocorticoid effects.
Oral progesterone (P4) formulations exist but with a very low bioavailability 
(<10%) because of rapid intestinal and liver metabolism. After oral administra-
tion of P4, low circulating concentrations of P4 contrast with the high concentra-
tions of its metabolites, notably 5α-reduced metabolites which are known sources 
of neuropsychological effects [34], reconsidered actually for neuroprotection. 
The micronization of the P4 molecule provides an optimal bioavailability, which 
depends both on the size of the P4 particles in suspension and on the nature of the 
oily excipient [35]. The vaginal route for micronized P4 was proposed since many 
years ago [36], but the new hypothesis regarding the higher endometrial P4 levels 
than that obtained after intravenous administration was presented by [37], being 
considered an opportunity for MHT. This phenomenon of preferential uterine 
distribution after vaginal administration was named “first uterine pass effect” 
[38], or “uterine specificity of vaginal progesterone” [39]. Although the serum P4 
concentration is often low or “up-physiological”, the endometrium shows clear and 
complete secretory changes, in the majority of treated cases.
The proposed mechanisms for explanation were done after many experimental 
and clinical studies: direct diffusion through tissue, intracervical aspiration, absorp-
tion into the portal venous system, or lymphatic circulatory system, and countercur-
rent vascular exchange with diffusion from utero-vaginal veins/lymph vessels to the 
arteries—all these mechanisms to concur in various extents to the “uterine specificity 
of vaginal progesterone.” Nasal administration of P4 is inducing comparative serum 
levels, but the endometrial secretory transformation is incomplete [40].
Previous studies showed that P4 absorption from the vagina is dependent on the 
formulation used and on the estrogen treatment [41]. The micronization of P4 is 
very important, and the oral micronized progesterone capsules were re-directed to 
be used vaginally [42]. Micronized P4 has a more selective effect on PRs and results 
in less interaction with androgenic and mineral-corticoid receptors compared with 
other progestogens. The previous administration of estrogens to vaginal micronized 
P4—100 mg/200 mg—is sustaining endometrial secretory effect compared with 
many other more potent progestogens. Recent evidence suggests that MHT regi-
mens containing micronized P4 can minimize the metabolic impact and reduce the 
risk of thromboembolism and side effects associated with progestogens [29].
There are considerable debates about whether and at which dosage micron-
ized P4 provides effective endometrial protection if applied orally, vaginally, or 
Recommended doses of micronized progesterone for endometrial protection in MHT
Route Dose Safe use/month and total duration of use
Oral 200 mg/day 12–14 days/month up to 5 years
Transdermal — Does not provide endometrial protection
Vaginal Sequential 45 mg/day or continuous 
combined 100 mg/day
10 days/month or every other day for up to 
3–5 years (off-label use)
Adapted from Ref. [44].
Table 1. 
Comparison of oral and vaginal route, and dosages of P4 administration for endometrial safety.
7Endometrial Histology and Safety on Non-Oral Routes of Hormone Therapy...
DOI: http://dx.doi.org/10.5772/intechopen.89046
transdermally [43]. Stute P at al. [44] are presenting the international expert panel 
recommendations on MHT containing micronized P4, based on their systematic 
review of the actions of micronized P4 on the endometrium. Table 1 presents the 
comparison of daily dose, number of days imposed for endometrial protection, and 
time duration of safety use.
1.1.4 Medicated intrauterine systems
The medicated intrauterine systems with levonorgestrel or with P4, actually 
accepted by many menopause societies, are minimizing systemic progestogenic 
side effects by direct release of progestogen/progesterone into the endometrial 
cavity and directly opposing the estrogens—natural or from HT. It is presented an 
endometrial protection which is equivalent to that provided by systemic continuous 
progestogen administration, and superior to sequential progestogen regimen [45].
2.  Endometrial safety on MHT: history, regimens, endometrial 
assessment, and endometrial histology during MHT
2.1 History
The review of climacteric symptom alleviation in the medical literature shows 
that the attempts are approximately 100 years old, starting with ovarian extracts, 
but in time it was demonstrated the ovarian responsibility for endometrial growth 
up to adenocarcinomas, as in ovarian transplantation [46] or in estrogen secret-
ing ovarian tumors [47–49], cited by Van Gorp and Neven [50]. Long time it was 
a minimal knowledge on the real estrogen dose per day to correct the menopausal 
estrogen insufficiency, and on the imposed dose of progesterone to balance 
endometrial estrogen induced proliferation [51], for prevention of endometrial 
hyperplasia and cancer [52, 53]. After observational, cohort, and animal studies 
were designed large prospective RCTs, as it was WHI with 2 arms, closed early than 
it was intended initially. After a proper WHI patient reanalysis, new perspectives 
were discovered for the medical communities of medical staff and women.
The post-WHI analysis [54] discovered a high incidence of endometrial cancer 
[55], specially an increase over time in women aged 50–74 years (with an annual 
percentage change, in 2004–2009: 2.8%; in 2005–2009: 3.3%; and 2006–2009: 
4.2%) [56], parallel to the decrease in the use of FDA-approved estrogen plus pro-
gestogen HT and parallel to the increase of endometrial hyperplasia [57], and after 
the increasing usage of compounded bioidentical HT (CBHT) instead of pharmaco-
logical products [58, 59], even if CBHT are not approved by the FDA, because both 
hormone compounds lack of standard [type (estrogen: is E2 or E3), dosage, (under 
dosage), and underpotency (for progesterone)] [60].
The number of cases with hyperplasia/endometrial cancer analyzed in different 
studies was small, fact that gives us contradictory results on endometrial safety 
on MHT, and there are few analyses on non-oral MHT. The largest prospective 
study to date on over 700,000 women, Million Women Study [61], which had done 
information on HT, reported a 30% reduction in risk associated with continuous 
regimens (based on 73 cases), but other observational studies have shown either no 
association or increased risks with use of continuous regimens, and some stud-
ies showing evidence of a dose-response relation with increasing duration of use 
(≥10 years) or increasing progestin dose. Compared with never users of HT, the 
risk was: reduced with last use of continuous combined preparations [RR = 0.71 
(95% CI 0.56–0.90); P = 0.005].
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The “European Prospective Investigation Into Cancer and Nutrition” [62] 
analyzed the association of various types of HT with the risk of endometrial 
cancer among 115,474 postmenopausal women, during 1992–2000, and after a 
mean follow-up period of 9 years, 601 incident cases of endometrial cancer were 
identified. In comparison with never users of HT, risk of endometrial cancer was 
increased among current users of E-only HT, with (HR = 2.52, 95% CI: 1.77–3.57), 
and, to a lesser extent, E + P use (HR = 1.41, 95% CI: 1.08–1.83), although risks 
differed according to regimen, and type of progestin constituent. The finding of a 
strong increased risk of endometrial cancer with estrogen-only HT, and a weaker 
association with combined HT supports the hypothesis that progesterone/progesto-
gens have an attenuating effect on endometrial cancer risk.
The North American large prospective “Diet and Health” Study of National 
Institutes of Health-AARP (NIH-AARP) [63] among 19,131 North American post-
menopausal women reporting exclusive E plus progestogen use, between whom 176 
cases developed endometrial cancer (RR = 0.88; 95% CI: 0.74–1.06), and the HRs 
for different regimens HT showed a little increase in comparison to the previous 
European Study. Long-duration (≥10 years) sequential E+ P (<15 days P/month) use 
was positively associated with risk (RR = 1.88; 95% CI: 1.36–2.60), whereas continu-
ous E + P use (>25 days P/month) was associated with a decreased risk (RR = 0.64; 
95% CI: 0.49–0.83). The American authors’ opinion is that findings support the fact 
that specific used categories of E+P increase the endometrial cancer risk: specifically 
long durations of sequential progestogens, whereas decreased endometrial cancer risk 
was observed for users of short-duration continuous progestogens add to estrogen.
The National Institutes of Health-AARP Diet and Health Study cohort, which 
did the follow-up for endometrial cancer risk after WHI’s premature closure, [64] 
did confirm a statistical reduction of endometrial cancer risk after continuous 
combined oral MHT for 5.6 years (RR = 0.85; 95% CI, 0.53–1.36), with normal 
endometrium at entry, and including women in the highest BMI groups; this review 
was done because the data were not clear after immediate publication of WHI 
(2002, 2004).
Parallel to these data, the “European Prospective Investigation Into Cancer 
and Nutrition” shows a strong association of risk among women who were older, 
leaner, or had ever smoked cigarettes [62], and the North American studies show 
an increased risk for sequential E + P only among thin-to-normal weight women 
(BMI < 25 kg/m2; RR = 2.53) [63]. California Teachers Study [65] reports that 
continuous-combined MHT was confined to thinner women (BMI < 25 kg/m2) (P 
for interaction: 0.03), and among heavier women (BMI ≥ 25 kg/m2), use of con-
tinuous-combined EPT was associated with a statistically nonsignificant reduction 
in risk, fact that is different from what was assumed in normal weight women. The 
association between endometrial cancer risk in continuous-combined MHT users to 
patients’ BMI is correlated to women’s lower endogenous estrogen levels, suggest-
ing that menopausal hormones and obesity increase endometrial cancer through 
common etiologic pathways, as was recently considered that a BMI ≥ 25 kg/m2 is 
increasing the rate of recurrence in patients hormonally treated for complex hyper-
plasia/carcinoma (P = 0.0004, OR 0.4; 95% CI: 0.3–0.6), or early stage carcinoma 
(P = 0.0000, OR 0.3; 95% CI: 0.2–0.6) [66] (Figure 2).
Healthy lifestyle index including diet, alcohol consumption, physical activity, 
body mass index, cigarette smoking, is recently correlated to endometrial cancer 
risk in Canada [67] and USA [68], and higher scores reflecting a healthier behavior 
of postmenopausal women are associated to reduction of endometrial cancer risk of 
various intensity according to the degree of type 1 cancer differentiation. Each unit 
increase in the HLI score was associated with 3% and 5% reductions in risk of post-
menopausal endometrial cancer risk (HR 0.95; 95% CI: 0.90–0.99). The American 
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HLI showed that after a median follow-up of 17.9 years there were 1435 endometrial 
cancer cases, and women in the highest quintile of the HLI score had a lower risk 
of overall, type I, well-differentiated, moderately differentiated, poorly differenti-
ated, and localized endometrial cancer than those in the lowest quintile [for quintile 
5 vs. quintile 1, HR = 0.61 (95% CI: 0.51, 0.72), HR = 0.60 (95% CI: 0.49, 0.72), 
HR = 0.66 (95% CI: 0.46, 0.96), HR = 0.69 (95% CI: 0.52, 0.90), HR = 0.49 (95% 
CI: 0.34, 0.72), and HR = 0.61 (95% CI: 0.50, 0.74), respectively].
2.2  Regimens of MHT: uterine bleeding on perimenopausal/menopausal 
hormone therapy
The chapter will discuss MHT with non-oral administrated natural estrogens 
which are available for perimenopausal and postmenopausal women, in comparison 
to oral available drugs, including contraceptive pills, among which there are some 
with natural estrogens, as are the estrogens in MHT. The history of MHT describes 
three types of MHT systemic regimens with estrogens and progesterone/progestogens 
for women with intact uterus, and only one systemic regimen with natural estrogens 
in hysterectomized women. Exogenous hormones are influencing endometrial cycle, 
and may also influence uterine volume, fibroid growth, polyps, endometriosis, and 
the development of cervical adenocarcinomas [50]. Progesterone/progestogens are 
mandatory for endometrial protection, as it is known since long time. Regarding 
endometrial safety one must discuss the characteristic of uterine bleed which appears 
in conjunction to the type of regimen, and the medical staff must counsel patients.
2.2.1 Sequential combined estrogen-progesterone/progestogen therapy
The sequential/cyclic administration of HT has minimum 10 days of progester-
one/progestogen, more safe is 12–14 days. In this regimen both hormones are oral 
or non-oral administrated, or only one is on a non-oral route. If the last menstrual 
period occurred less than 1 year prior to starting MHT, a sequential combined 
regimen should be started, i.e. continuous estrogen with progesterone/progestogen 
for 12–14 days per month [29]. Thereby reducing the risk of endometrial hyperpla-
sia. The patients will have a monthly withdrawal bleed with this regimen, which 
usually starts from the 11th day of progesterone/progestogen when this administra-
tion is for 10 days [69], and the endometrial thickness at transvaginal sonography 
Figure 2. 
Hazard ratios (HRs) for risk of endometrial carcinoma (black squares) according to use of menopausal 
hormone therapy (HT), by recruitment center and age, European Prospective Investigation into Cancer and 
Nutrition, 1992–2006. The size of each square is inversely proportional to the variance of the logarithm of the 
relative risk. HRs were adjusted for body mass index, parity, age at menopause, and oral contraceptive use. 
Bars, 95% confidence interval (CI). Adapted from Ref. [62]. Permission of Oxford Publishers.
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(during the progestin administration) is higher than 4 mm at least in the first year 
of use [70]. Prescription of cyclic transdermal/percutaneous E2, and the sequential 
addition of natural progesterone or a synthetic progestogen induces artificial cycles 
with regular withdrawal bleeding.
2.2.2 Continuous combined estrogen-progesterone/progestogen therapy
Both hormones are administered oral or non-oral, or only one is non-oral. These 
regimens are increasingly used early in postmenopausal women, and the large long 
term Medical Research Council randomized controlled trial on HT, the Women’s 
International Study of Long Duration Estrogen after the Menopause, and the WHI 
study in the USA are based on this type of oral treatment, being accepted also for 
women with endometrial hyperplasia without atypia. This type of regimen is dis-
cussed after a minimum 6 [69] to 12 months of sequential MHT [29] or 1 year after 
the last menstrual period (2 years in women with premature ovarian insufficiency). 
Women who wish to avoid a monthly withdrawal bleed may attempt a switch to 
a continuous combined regimen, which aims to give bleed-free MHT. This will 
minimize also the risk of endometrial hyperplasia, as it was previously discussed. 
There may be some erratic bleeding to begin with, but on persistence with continu-
ous combined regimens 90% of women become bleed free.
British Menopause Society [20] has some recommendation for some special 
situations with uterine bleeding on continuous combined HT, as follows:
• If breakthrough bleeding occurs following the switch to continuous combined 
HRT and does not settle after 3–6 months, then the woman can be switched 
back to a sequential regimen for at least another year.
• If bleeding is heavy or erratic on a sequential regimen, the dose of progestogen 
can be doubled or duration increased to 21 days.
• Persistent bleeding problems beyond 6 months warrant investigation with 
ultrasound scan, and endometrial biopsy if clinically indicated.
2.2.3  Cyclic hormone replacement therapy using quarterly progestogen during 1 
year or long cycle hormone replacement therapy
By the year 1994, Ettinger B (USA) proposed a cyclic hormone regimen with 
quarterly progestogen instead of monthly, aiming endometrial protection from 
hyperplasia and cancer, fact that was accomplished by 10 mg/day of MPA for 
14 days at every 3 months [71], and with gestodene 50 μg for the last 12 days of 
84 days with continuously 17β E2 in different doses—1 or 2 mg/day, with 1 year 
duration in the Netherlands [72]. These studies reported less bleeding episodes, 
with longer duration, and similar high number of hyperplasia compared to baseline 
assessment. In the Nordic countries this type of MHT regimen is popular, and the 
Scandinavian study [73] with a duration of 4 years reported partially similar results, 
but they used norethindrone acetate at a dose of 1 mg/day, for 10 days associated 
to 17β E2 2 mg per day, reduced to 1 mg day during the last 6 days of each cycle 
of 12 weeks. They reported a higher rate of drop-out due to bleeding vs. monthly 
progestogen (P < 0.01), and hyperplasia incidence of 5.6% vs. 1% in the monthly 
group (P = 0.003), with 1 case of atypical hyperplasia, and 1 case of endometrial 
adenocarcinoma. The popularity of this regimen is correlated to the 2-fold eleva-
tion of endometrial cancer risk in Finland population, and the risk reduction after 
cessation of the regimen [74].
11
Endometrial Histology and Safety on Non-Oral Routes of Hormone Therapy...
DOI: http://dx.doi.org/10.5772/intechopen.89046
Besides these analyses, there is no proper study on non-oral administrated 
hormones, neither estrogens or progesterone/progestogen, because the Spanish study 
[75] assessing endometrial stability by the rate of amenorrhea and endometrial stim-
ulation is monitoring the intermittent administration of 100 mg vaginal micronized 
progesterone to a patch delivering low-dose estradiol (25 μg/day). According to the 
Scandinavian data on hyperplasia and cancer risk [76, 77] in long cycle progesterone/
progestogen regimen the bleeding pattern is not sufficient for endometrial safety, 
being mandatory endometrial monitoring with ultrasound and biopsies (Table 2).
2.2.4 Uterine bleeding on hormone therapy: is it predictive for uterine histology?
Women who start MHT from early stages of STRAW (−3 stage) may benefit 
from therapy with progesterone/progestogens, which balances their hormonal 
milieu, but starting replacement after 1 year amenorrhoea may induce the major 
disadvantage—the unpredictable bleeding and/or spotting, which are common in 
the early months of use, no matter what regimen is used. The unpredictability and 
persistence (in the short term) of bleeding and/or spotting is a common cause for 
discontinuation.
At the beginning of this century the Australian researchers [78] have presented 2 
patterns for bleeding when on MHT: scheduled “withdrawal” bleeding, or unsched-
uled “breakthrough bleeding”, usually for sequential, respectively for continuous 
combined regimen. Depending on the regimen, the endometrium may be prolif-
erative, secretory, near atrophic or a mixed picture, and bleeding may occur from 
either an estrogen-dominated or a progestogen-dominated endometrium. When 
recommending continuous-combined regimen after a long duration of amenorrhea, 
the incidence of breakthrough bleeding is high in the first 3–6 months.
Since many years it is considered that the bleeding pattern cannot be a good 
predictor for endometrial histology, and safety, but it is an exception with proges-
terone/progestogen withdrawal bleeding in the sequential regimens, after 3 to 6 
cycles of therapy, and when it is a complete secretory transformation, the bleeding 
may be cyclic in the last 5 days of progesterone/progestogen, or in the first 6 days 
of the next cycle [79]. Hyperplasia is not predicted by regular bleeding on HT, as a 
multicenter study suggests [80].
Hormone Preparation
Transdermal estrogen 17β-estradiol patch
17β-estradiol gel
17β-estradiol emulsion
17β-estradiol spray
Vaginal estrogen 17β-estradiol cream
Conjugated equine estrogen cream
17β-estradiol ring
17β-estradiol tablet
Estriol cream
Estriol soft capsules
Vaginal progesterone Micronized progesterone—soft capsules, gel
Transdermal progesterone/progestogens Norethindrone acetate
Levonorgoestrel
Progestin: intrauterine system Levonorgestrel
Progesterone
Table 2. 
Available non-oral estrogens and progesterone/progestogens for MHT.
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The variations of endometrial answers to transdermal estrogen and vaginal 
micronized progesterone are reduced in comparison to HT oral route, according 
to more stable transdermal/percutaneous estrogen serum levels, and progesterone 
uterine first pass. When the bleeding pattern is observed comparative to endome-
trial histology, the patients with proliferative histologic pattern are bleeding early 
than the patients with secretory transformation [81].
An Italian prospective study [82] evaluated and compared uterine bleeding in 
100 early postmenopausal women (12–36 months after last mensis) on a sequential 
regimen with both hormones administered non-oral, versus the same regimen with 
oral natural progesterone (NP). All groups were treated with transdermal 17β-E2 
50 μg/day, and the NP was 100 mg or 200 mg per day from the 14th day to the 25th 
day of each 28-day cycle. After 12 cycles of treatment, no significant differences 
were observed in endometrial thickness between groups, suggesting that all treat-
ments are effective in balancing the estradiol effects on endometrium. Regarding 
bleeding control, patients in the group with sequential vaginal NP showed a higher 
number of episodes of regular bleeding than patients in groups with oral NP, and 
fewer episodes of spotting. Authors’ conclusion was that transdermal estrogen 
combined with vaginal 100 mg micronized NP from the 14th day to the 25th day 
of each 28-days cycle leads to a good cycle control, and provides excellent patient 
satisfaction without serious side-effects. The better control of bleeding was associ-
ated with a higher treatment compliance in patients who received vaginal NP, with a 
larger percentage of women completing the study. The authors recommend to start 
treatment with the lower dose of NP (100 mg/day) to avoid the risk of amenorrhea 
with 200 mg/day.
An Italian study which is considered with the longest duration—3 years, has 
prospectively evaluated the bleeding/amenorrhea in 30 postmenopausal women 
treated with continuous transdermal E2 gel and every-other-day vaginal micron-
ized progesterone in capsules [42]. They report that 4 (13%) of 30 patients with-
drew from the study because of bleeding (3 for heavy bleeding and 1 for repeated 
spotting), and an higher incidence of amenorrhea (82%) than commonly reported 
(70%) with oral compounds [83].
2.3  Endometrial safety: endometrial assessment on MHT and endometrial 
histology on non-oral regimens of MHT
2.3.1 Endometrial safety
Endometrial safety is a grill for challenge menopausal and postmenopausal 
HTs, because the bleeding and the risks of hyperplasia and cancer are discussed in 
the 70 years of MHT history, years with many waves of increased and decreased 
enthusiasm on the benefits and risks of MTH. The aim of replacement and restora-
tion of ovarian functions in postmenopausal women with estrogens and progester-
one is only a modest attempt for women’s health, because there are missing other 
molecules as testosterone, activin, inhibin, anti-Müllerian hormone (AMH) and 
insulin-like growth factor 1 (IGF-1), and many other connected to these, which 
have an immense significance on a woman’s physiology, and all of them may influ-
ence endometrial actions of MHT [84].
The endometrial safety means the protection from non-invasive proliferative 
lesions—hyperplasia, and invasive—carcinoma.
• If the analysis of histological data is done after the criteria of the years 80′ the 
endometrium must be with secretory changes in the sequential regimens, and 
atrophy, or inactive after the continuous—combined regimens.
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• If the analysis of histological data is done after the criteria of the years 90′ 
endometrial safety means to reduce the risk of hyperplasia and carcinoma 
development, in fact to down-regulate estrogen induced proliferation, with 
disappearance of mitosis from the endometrial glands, and stroma, or ≤2 
mitoses at 1000 cells, the so-called proliferation index, or mitotic index [44].
The impact of vaginal progesterone on the endometrial safety is very important, 
being considered that the duration is more important than the dose [85]. After the 
results of the Scandinavian study regarding long cycle progestogen association 
to estrogen—at 3 months interval [86], which was updated in Cochrane Database 
Systematic Review [87, 88], today it is considered that it is important to combine a pro-
gesterone/progestogen with the estrogen in the beginning of the treatment, to control 
early endometrial growth. If one considers these Scandinavian studies, one may accept 
a non-opposed estrogen administration as Van Gorp and Neven recommend [50]. 
Minimum 10 days/month of vaginal administration provides protection in sequential 
regimens, in a dose of 45 mg/day at 4% in cream, or every other day in a dose of 
100 mg/day for up to 3–5 years (off-label use) [44], but this aim is not accomplished 
with transdermal micronized progesterone [89, 90]. The daily balance of non-oral 
estrogen by non-oral progesterone/progestogen in continuous combined regimens is 
more stable than the balance of oral administration, and endometrial carcinoma risk 
is also reduced, as since long time ago it was reported after 8 years of use [91]. If oral 
and non-oral routes of progesterone/progestogen administration are proved to be less 
effective in treatment of atypical endometrial hyperplasia, and unable to stop most 
early invasive cancers, the intrauterine system with levonorgestrel 20 μg /day associ-
ated to transdermal estrogens was demonstrated to achieve these aims after 3 years 
administration. From 20 Belgian women, only one asymptomatic women with atypi-
cal hyperplasia at baseline at 3 years was discovered with focal residual non-atypical 
hyperplasia, in the presence of a thin (<4 mm) endometrium [92].
In 2002, Van Gorp and Neven [50] have published in “Maturitas” the Journal of 
the European Menopause and Andropause Society a review of endometrial safety 
on MHT. They presented a Finish study [93] on the endometrial safety after short 
term HT (12 months) regarding percutaneous estradiol-gel delivering E2 1.0 mg/
day, or patch (delivering E2 50 pg/day) in a sequential regimen with oral dydroges-
terone 10 mg/day for first 12 days of the cycle. The endometrial biopsies—collected 
during the 9th to 12th days of the progestogen days in both groups did not revealed 
any hyperplasia, or any estrogenic effect.
2.3.2 Endometrial assessment on menopausal hormone therapy
MHT must be assessed when women start therapy, with an annual follow-up 
or when there is a minimal suspicion of endometrial abnormality regarding bleed-
ing, or when it is an abnormality at transvaginal scan by endometrial biopsy, with 
Pipelle Cornier suction curette, Kevorkian or Vabra curette, or by fractional curet-
tage—endometrium and endocervix, or by out-patient hysteroscopy. Hysteroscopy 
permits to avoid the loss of an isolated focus of endometrial cancer, atypical 
hyperplasia or polyp which easily can be missed by blind sampling procedures 
[70]. On another hand hysteroscopy is prone to depict the changes of endometrial 
surface, vessels, which are very much discussed by the Australian gynecologists and 
pathologist in connection to bleeding pattern on MRT [78].
Besides some inconvenients which will be discussed in the next subchapter, the 
endometrial sample obtained with Pipelle Cornier suction curette has been shown 
to be as accurate as conventional dilation and curettage in the diagnosis of endome-
trial pathology in premenopausal and postmenopausal women [94]. The amount 
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of endometrial tissue is very little, sometimes much less than that demanded by 
pathologists unused to such biopsies, but when the microscopy is corroborated to 
ultrasound, the medical staff can be reassured of safety [94].
Double layer endometrial thickness is usually measured at the thickest part in the 
longitudinal plane, by scanning from cornua to cornua. The poorly echogenic layer 
surrounding the highly echogenic endometrium is not included in the measurement. 
Endometrial thickness is evaluated to determine the mean of three measurements 
and excluding the possible endometrial fluid from the measurement. One must take 
into account in elder patients with atrophic endometrium after MHT that the fluid 
may be blood, even the patients do not bleed. In oral and non-oral MHT the endo-
metrial thickness has an initial increase—more important after sequential regimens, 
with a consistent decrease at 36 months when on continuous combined regimens, 
so the endometrium becomes significantly thinner than at baseline. These data are 
controverted by the previously presented prospective Italian study, which after 
12 cycles of non-oral sequential treatment discovered no significant differences in 
endometrial thickness between groups, suggesting that all treatments are effective 
in balancing the effects of percutaneous E2 on endometrium [82].
The prospective Italian study on continuous-combined non-oral MHT [42] 
revealed a smaller increase of the endometrial thickness comparative to that 
reported by a similar North American oral regimen; the baseline-to-endpoint 
increases in endometrial thickness were 7.8 ± 3.8 mm, and 1.8 ± 3.2 mm, respectively 
[95] versus the Italian data, where the mean endometrial thickness increase was 
only 0.7 mm, after 6 months treatment, and endometrial atrophy was registered 
after 3 years (end of study), in all cases that completed the study [twenty-three 
(76.7%) women from 30 healthy cases in natural menopause]. The British study 
[96] revealed a continuous increase of endometrial thickness from baseline [3.3 
(1.7)] mm to the mean of 5.3 (3.3) mm by 24 weeks (P < 0.001), and of 5.5 (2.8) mm 
after 48 weeks, with continuous combined transdermal E2 l.1 mg/day plus 4 mg/day 
NP cream, (P < 0.001), being a non-significant increase from 24th to 48th weeks, 
but the increase was more important when it was inadequate endometrial opposi-
tion (4.7 mm vs. 7.6 mm respectively, P < 0.001). These results and the histological 
aspects of proliferative endometrium with inadequate progesterone opposition after 
48 weeks HT—which will be analyzed in next subchapter, sustain the actual recom-
mendation to avoid transdermal natural progesterone.
2.3.3 Endometrial histology with non-oral MHT
Endometrial histological assessment is a very important part of the continuing 
follow up of women taking MHT. There are few studies on endometrial histology 
after MHT with both hormones administered non-orally in comparison to oral route.
Table 3 is listing such studies, which were published after WHI, with some 
North American studies before the year 2000; the studied estrogens and progesto-
gens were transdermal administered, and the soft capsules of micronized proges-
terone were vaginally administered. Because it is the rule of baseline endometrial 
assessment, the studies are comparing the histology at pre, and post-treatment, or 
in some of them to oral MHT. The endometrial biopsy is done before treatment, 
and between 9th and 14th days of treatment cycle, to evaluate the progesterone/
progestogen effect (similar to cases on oral MHT), in the sequential regimens. The 
endometrial specimen is collected after 6 months, no matter which day, in continu-
ous-combined MHT regimens.
Endometrial safety is assessed in terms of prevention of estrogen-induced 
hyperplasia. Progesterone supplementation may cover the objective of endometrial 
protection from benign hyperplasia from the STRAW—3 stage (2012), or when it is 
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Authors/study 
group, year
Duration of use
Type and dose of 
estrogen
Type and dose 
of progestegen/
progesterone
Hyperplasia, type 1/2 cancer
P value
(authors conclusions/
commments)
Archer DF, Furst K, 
et al., 1999 [97]
3, 6, 9, and 12 months 
after initiation of 
treatment
Continuous combined 
estradiol 50 μg/day
Norethindrone acetate 
140, 250, or 400 μg/day
0.8% (1 of 123), 1% (1 of 98), 
1.1% (1 of 89)
(P < 0.001)
Ylikorkala O, 
Rozenberg S, 2000 
[98]
12 months
Continuous combined or 
sequential E2 50 μg/day
Continuous combined 
Trd NETA: 170 μg/
day or sequential Trd 
NETA: 350 μg/day, or 
sequential oral NETA 
1 mg/day or sequential 
DYD 20 mg/day
2 cases of simple hyperplasia 
were reported (1 in each low-
dose progestogen group)
Shulman LP, Yankov 
V, Uhl K, 2002 [99]
12 months
Continuous combined, 
once a week patch E2 
0.045 mg/day
LNG mg/day of 0.015; 
0.030; and 0.040
No hyperplasia
Sturdee DW, van de 
Weijer P, von Holst T, 
2002 [100]
12 months
Sequential: 3 groups
1.  patches of 15 cm2 (50 μg/day E2 for 2 wks, 
followed 50 μg/day E2–10 μg/day LNGl for 2 wks
2.  22.5 cm2 (75 μg/dy E2 for 2 weeks followed by 
75 μg/day E2–15 μg/day LNG for 2 wks)
3.  30 cm2 (100 μg/day E2 for 2 wks followed by 
100 μg/day E2–20 μg/day LNG for 2 wks)
Endometrial protection for all 
groups
Dando TM, Perry CM 
(2004) [101]
17 beta-E2/LNG 
transdermal system
12 months, RCT
Continuous combined, 2 groups with once a week 
Patch 17 β estradiol:+ LNG 4.4/1.39 or 4.4/2.74/day or 
4.5/3.75 mg/day
No hyperplasia
Cicinelli E, de Ziegler 
D, Colafiglio G, et al., 
2005 [42]
3 years montoring
Continuous combined 17 
β estradiol gel, 1.5 mg/day
Micronized 
progesterone, soft 
capsules 100 mg every-
other-day (or at 48 h) 
(vaginal)
No hyperplasia
Atrophy: 100%
Vashisht A, 
Wadsworth F, Carey 
A, Carey B, Studd J, 
2005 [96]
48 weeks (54 cases, 
only 41 completed 
the study)
Continuous combined 
oestradiol 1 mg/day 
transdermal daily
Natural progesterone 
cream 40 mg/day 
(transdermal)
10 (27%) endometrial 
proliferation, 2 (5%) complex 
hyperplasia, 1 with (mild) 
atypia, and 1 without atypia
Samsioe G, Dvorak 
V, Genazzani AR, 
et al., Estalis 25/125 
Study Group, 2007 
[102]
96 weeks
Continuous combined 
estradiol matrix 25 μg/day
NETA 125 μg/day No hyperplasia
No cancer
Russu M, Terzea D, 
Hudiţă D, 2009 [103]
24 months 
monitoring
Sequential HT
1.  Group oral: 2 mg/d E2 valerate (E2V) 21 days, E2V 
plus CYP 10 days
2.  Group oral: 2 mg/d -mcr E2 14 days, 2 mg/d mcrE2 
plus DYD 14 days
3.  Group mixed: 17β E2 patch (25 μg/d 21 days) plus 
oral MPA (10 mg/5 mg/day) last 12 days
4.  Group fully non-oral: 1 g/d 17β E2 gel 28 days plus 
200 mg/d vaginal micronized VMP last 12 days
1 case with simple hyperplasia 
without atypia after 24 months, 
on transdermal estrogen +5 mg 
MPA
(incidence 1/43 cases) is inside 
the oncological safety (2 
cases/100 women year)
No carcinoma
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the onset of menstrual cycle irregularities, which may have hyperplasia as histologic 
substrate.
The effects of hormones are appreciated on the architecture and cytological 
aspects of the epithelium, glands, stroma, and vessels. Mitoses are considered for 
estrogens proliferative effect, and subnuclear glycogen accumulation, and intralu-
minal secretions for high grade progesterone effects, or the cytoplasmic vacuolisa-
tion, for low grade progesterone secretory change [104, 105]. When progesterone 
regulation effect is not possible to be assessed with accuracy, the degree of prolif-
eration suppression—mild, moderate, strong is a surrogate for evaluation, as it was 
done in the Romanian analysis [103].
There are many pathologists involved in endometrial assessment on/after MHT 
in Europe, USA, Canada, South Africa. Table 4 presents an adaption of endometrial 
changes on MHT according to International Society of Gynecological Pathologists 
(2019) [112, 113], WHO (2014) cited by [123], British Society for Gynecological 
Endoscopy (2014) [120], FIGO (2009, 2012) cited by [119]. Deligdish [104], Feeley 
and Wells [94] present very understandable the endometrial effects of MHT, 
including a wide spectrum of morphologic features, known since long time on oral 
MHT, and less on non-oral routes, which are. Recently discussed by Owings and 
Quick [105]. For simplicity of understanding, Table 4 contains the classification 
of endometrial histology changes, with special attention to the hyperplasia [WHO, 
1994, with 4 types updated by WHO, 2014, cited by [123], which was recommended 
for use by the Royal College of Obstetricians and Gynecologists (RCOG), and the 
British Society for Gynecological Endoscopy (BSGE) [120], with only 2 catego-
ries, as it is mentioned in the table, and it was discussed at the beginning of the 
subchapter].
The first three types (unassessable, inactive, atrophic) may impose some prob-
lems to the pathologist, because there is a small amount of tissue—obtained with 
Pipelle suction curette, and the British pathologists Feeley and Wells [94] appreciate 
that this condition can be associated to thin, regular endometrium at hysteroscopy, 
or with an endometrial thickness not exceeding 7 mm, at sonography [108], and 
though the pathologist can therefore be reassured that where the endometrial cavity 
has been entered and little or no endometrial tissue is obtained, there is very little 
likelihood of important endometrial pathology to be present. The assessment of 
secretory endometrium may be confused by artifacts of fragments disruption, 
which may induce focal changes of glandular tortuosity and crowding. The diag-
nosis of low grade cytological atypia is very difficult to be appreciated [94]. In a 
progesterone/progestogen rich environment, nuclei of premalignant glands tend to 
diminish in size, and acquire a rather bland chromatin pattern, which makes them 
Authors/study 
group, year
Duration of use
Type and dose of 
estrogen
Type and dose 
of progestegen/
progesterone
Hyperplasia, type 1/2 cancer
P value
(authors conclusions/
commments)
Fernandez-Munga 
L, Hermenegildo C, 
Tarin JJ, Garcia-
Perez M-A, Cano A, 
2012 [75]
12 months
Intermittent (twice a 
week)
Estradiol patch
25 μg/day
Intermittent (twice a 
week)
100 mg micronized 
progesterone (vaginal)
No apparent endometrial 
stimulation
E2, estradiol; LNG, levonorgestrel; NETA, norethisteron enanthate; E2V, estradiol valerate; CYP, cyproterone acetate; 
DYD, dydrogesterone; VMP, vaginal micronized progesterone.
Table 3. 
Studies on endometrial histology and safety after non-oral routes of MHT.
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appear less “atypical”. Paradoxically, the nuclei of normal glands become enlarged 
and rounded—features associated with atypia [109].
The endometrium aspect depends on the regimen; it may be proliferative, secre-
tory, near atrophic, inactive, or a mixed picture-mixed proliferative and secretory 
endometrium including crowded and hyperplastic glands, alternating with an 
edematous, hyperplastic, or decidualized stroma, sometimes with thickened or 
thrombosed blood vessels.
Most endometrial biopsies from women on sequential MHT show weak secre-
tory features. Approximately 15% show proliferative activity, although this figure 
may be less if more than 9 days of progesterone/progestogen is given per cycle. A 
small proportion are revealing an inactive or atrophic endometrium. Up to 50% of 
biopsies in cases on continuous combined HT contain minimal tissue for pathologi-
cal analysis: this correlates well with an atrophic endometrium with no appreciable 
pathology. Of the 50% with more substantial material, approximately one half 
presents endometrial atrophy, and one half are showing weak secretory features 
[94]. The Romanian analysis shows that after complete non-oral route of HT, the 
proliferative rate and secretory changes were more frequent in the first year, and 
Unassessable
• No tissue identified
• Tissue insufficient for diagnosis
• No endometrium identified
• Endometrial tissue insufficient for diagnosis
Inactive
• Narrow tubular glands lined with cuboidal epithelium
Atrophic
• Cystically dilated glands lined by single layer of inactive, flattened epithelial cells
Proliferative
• Presence of epithelial mitoses
Secretory
• Epithelial cytoplasmic vacuolation—subnuclear or supranuclear
• Glandular luminal secretion in mid-phase and late phase
Pseudo-decidual change
• Typical stromal decidual change associated with inactive or weakly secretory glands, induced by 
progestogen
Benign hyperplasia (BH), Mutter [106] or endometrial hyperplasia without atypia (WHO, 2014), which 
covers formerly named simple and complex hyperplasia without atypia (WHO, 1994)
• Simple hyperplasia without atypia:
• Dilated glands with increased nuclear stratification of lining epithelium and increased stromal mitoses.
• No risk of malignancy
• Complex hyperplasia without atypia
• Crowded and irregular branched glands
• Low risk of malignancy
Atypical endometrial hyperplasia (WHO, 2000), or endometrial intraepithelial neoplasia (EIN)—[106, 107]
• Atypical epithelial cells; high risk of malignancy
Carcinoma (endometrioid type, non-endometrioid type)
Adapted from WHO (2014) which updated WHO (1994); [106, 107, 121].
Table 4. 
Classification and associated features of histological examination of the Pipelle endometrial biopsy.
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atrophy was after oral HT. The analysis regarding endometrial stroma has revealed 
two important aspects to be discussed:
• the increase of stroma the fibroblast-fibrocytic proliferation, and the reduction 
of fibrosis in all treated cases, indirectly the maintenance of the stroma volume 
(an important criteria when on discuss about EIN, with volume percentage 
of stroma <55%). This change makes the difference between normal cycling 
endometrium and the iatrogenic one.
• the increase of the granulocyte inflammatory reaction, which is like a pseudo-
decidualisation, not a sign of endometritis, which need to discover the presence 
of periglandular plasma cells, and leukocytes. In the natural menstrual cycle 
the presence in endometrial stroma of the leukocytes infiltration is normal in 
the premenstrual phase, when starts the decline of estrogen and progesterone, 
aspect which is rarely discovered, but it is discussed also by Deligdish [104] in 
sequential regimens, as a probable result of the iatrogenic hormones withdrawal.
3.  Endometrial hyperplasia and endometrial cancer risks in MHT: 
immunohistochemistry for biomarkers of endometrial transcriptome 
in MHT
3.1 Endometrial hyperplasia and cancer
Endometrial cancer is the fourth cancer in women from developed countries 
[110], and actually there are 2 types of endometrial cancer, with different natural 
history, carcinogenesis and evolution.
According to the molecular mechanisms, to the dualistic model of endometrial 
cancer development, first time described by Bokhman [111], the last classification 
at the Endometrial Cancer Workshop sponsored by the International Society of 
Gynecological Pathologists in 2016 [112], and the most recent discussion of the 
International Society of Gynecological Pathologists in 2019 [113] describes low 
grade and high grade endometrial cancers, both types being discussed to have MHT 
in perimenopause and late postmenopausal stages of women’s life.
• low grade or type 1 or endometrioid endometrial or the “indolent” cancer, 
which is estrogen dependent, has “atypical endometrial hyperplasia”, as pre-
cursor (23% cases progress to endometrioid adenocarcinoma), a monoclonal 
lesion, with microsatellite instability, and ras and PTEN mutations [106, 107, 
109, 114, 115], and PTEN gene loss in up to 65% cases with EIN and in 85% 
cases with endometrioid carcinoma [116], with estrogen and progesterone 
receptors at immunohistochemistry analysis [110] discovered more frequent in 
white, Caucasian women.
• high grade endometrial carcinomas or type 2 are represented by previous 
FIGO grade 3 endometrioid carcinoma, serous endometrial carcinoma, clear 
cells endometrial carcinoma, undifferentiated/dedifferentiated carcinoma, 
and carcinosarcoma. They are non-estrogen dependent, more aggressive, with 
atrophia or with a polyp rather than hyperplasia as precursor, and they are 
non-responsive to progestins [32]. They contain p53 mutations and abnormal 
accumulation of p53 protein, and absence of ERs, PRs [117, 118]. In cases with 
serous endometrial carcinoma the estrogen level is low, but SHBG is high, 
women are 6 years elder, with lower BMI than the cases with type 1.
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The FIGO grading 1, 2 and 3 of endometrioid endometrial adenocarcinomas 
are actually nominated only in two grades, as follows: former grade 1 and 2 are the 
actual “low” grade endometrioid endometrial carcinomas, and former grade 3 is the 
actual “high grade” [119], although FIGO, the ACOG, and the College of American 
Pathologists are considering this grading as standard.
Hyperplasia and endometrioid endometrial cancer risk is associated to excess 
levels of estrogen, or to non-balanced/non-opposed estrogens by progesterone/
progestogens-proved by PEPI trial (1996) [122], after the well-known paper 
of Kurman et al. [32], and recently reconfirmed by the “European Prospective 
Investigation Into Cancer and Nutrition” [62]. Mutter [106, 109] is describing 
benign hyperplasia—with low risk for malignancy, type that was discovered in the 
studies listed in Table 3 and “Endometrial Intraepithelial Neoplasia” (EIN) the 
precursor for the endometrioid endometrial/type 1 cancer.
The terminology of “Endometrial Intraepithelial Neoplasia” (EIN) [109, 116] 
was previously termed in the World Health Organization system (1994) as atypical 
endometrial hyperplasia — simple, and complex. There is no direct concordance of 
WHO to EIN categories because the two strategies employ different criteria that are 
often nonequivalent [123]. On must remember that approximately 50% of women 
diagnosed with atypical hyperplasia have concurrent carcinoma [124].
The WHO (1994) system largely relies on relatively fixed notions of how atypi-
cal endometrial cells appear, whereas an EIN criterion combines crowded architec-
ture and a relative change in cytology in the high-risk category.
“Endometrial Intraepithelial Carcinoma” (EIC) [125] is considered as precursor 
for high grade/type 2 endometrial cancer, and it represents malignant transforma-
tion of atrophic surface endometrium, discovered in 89% of cases. “Endometrial 
intraepithelial neoplasia” should never be confused with “endometrial intraepithelial 
carcinoma”, which refers clearly to type 2 endometrial cancer, usually named as serous 
carcinoma, and is driven by a p53 mutation. Awareness of these 2 entities and their 
histologic features is critical for avoiding misclassification [109, 118].
The data regarding endometrial hyperplasia/cancer on or after non-oral route 
of MHT are few, but generally they may be comparable to those on oral drugs. 
The Finnish Cancer Registry [74], which evaluated cancer risk from 1995 to 2007 
recorded 1364 type 1 and 38 type 2 endometrial cancers by the end of 2006, and the 
study analyzed duration and type of regimen, route and type of progestogen: oral/
non oral sequential (10–14 days once a month—“monthly sequential” or every three 
months—“long-cycle”), or continuous combined (E2 patch or gel plus NETA or 
LNG), or E2 transdermal + LNG-releasing intrauterine device system (LNG-IUS).
• For use of <5 years, the OR for sequential EPT was 0.67 (95% CI: 0.52–0.86), 
for continuous E2+ P was 0.45 (CI: 0.27–0.73), and for E2 plus LNG-IUS = 0.39, 
CI: (0.17–0.88).
• A decreased risk persisted for the use of continuous E2+ P and E2 plus LNG-
IUS of up to 10 years.
The conclusion of the Finnish study was that the use of a continuous rather 
than a sequential E2-progestogen regimen decreases the risk of endometrial cancer, 
whereas the route of administration or type of progestin does not differ in terms of 
endometrial cancer risk.
A recent North American study [126] revealed that compared with non-MHT 
users, cases who reported using E+ P Therapy had lowered all-cause (HR = 0.65, 
95% CI = 0.43–0.99) and endometrial cancer-specific mortality (HR = 0.51, 95% 
CI = 0.26–0.98), study which can be added to a previous study from Sweden [127], 
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which investigated tumor grade and depth of myometrial invasion, and 5-year rela-
tive survival in postmenopausal endometrial cancer patients. In this analysis, ever 
use of any MHT entailed lower risks of having moderately and poorly differentiated 
tumors. The lowest OD for poorly differentiated tumors were seen for ever users of 
cyclically combined estrogen-progestin [OR = 0.23 (95% CI: 0.07–0.73)]. Ever users 
of any form of MHT, particularly medium potency MHT users, had significantly 
lower risks for tumors with deep myometrial invasion, and adjusted estimated rela-
tive excess HRs revealed significantly improved survival for ever users of any form 
of MHT [RER = 0.40 (95% CI: 0.16–0.97)]; in particular ever users of any form of 
oestrogens [RER = 0.38 (95% CI: 0.15–0.99)]. The authors’ conclusions were that 
MHT ever used induces a more favorable tumor characteristics, less aggressive and 
with better patients’ survival.
3.2  Immunohistochemistry for hyperplasia and endometrial cancer risk on 
MHT: endometrial transcriptome and biomarkers
Endometrium is a tissue with strong capacities of renewal/remodeling for cell 
proliferation/new tissue formation, differentiation, apoptosis, angiogenesis which 
are highly regulated by ovarian steroids, and various locally expressed gene prod-
ucts, and with the presence of regenerative endometrial stem cells with their special 
capacities, which are maintained in menopause. The role and qualities of endome-
trial stroma in EIN, and cancer progression are very important, and the mecha-
nisms of E and P4 in promoting proliferation on one side, secretory activity and 
differention on the other side are connected to the steroid receptors presence, and 
to the transformation of endometrial transcriptome, because of gene or epigenetic 
changes by hypermethylation of DNA and histones, with overexpression or under-
expression of genes that encodes the proteins necessary for successful proliferation, 
apoptosis, angiogenesis, and fight against endometrial epithelial glands and stroma 
atypia The reported “hyperplasia” and no endometrial cancer from Table 3 is not 
sufficient for the outcome prediction for long time. Molecular genetic researches 
related to hereditary predisposition (as Lynch syndrome, and Cowden syndrome) 
and to epigenetic changes are now used for uterine structures too, and endometrial 
transcriptome is more and more understood.
There are histological biomarkers for endometrial transcriptome assessment: 
estrogen (ER), progesterone (PR) receptors, membrane estrogen and progesterone 
receptors, and their polymorphism; enzymes involved in E2 metabolism to E1, and 
other molecules as bcl-2, p53, PAX-2, PTEN, VGEF, and microRNA (miRNA) can 
help to make the differences in the outcome of each patient. The proliferative activ-
ity induced by estrogen increases the risk for errors in transcription (microsatellite 
instability, K-ras mutation, PTEN gene mutations), which are essential for carcino-
genesis [128]. Microsatellite instability (MSI) is a condition manifested by damaged 
DNA because of defects in normal DNA repair process; it induces progression of 
hyperplasia with atypia to endometrioid endometrial carcinoma—reported to be 
20–45% in such cases, and 0–11% in type 2 endometrial carcinoma.
Estrogen may operate through “classical” genomic pathways (via nuclear ERs) 
or non-genomic pathways (ERs in plasma membrane/cytoplasm or other receptors/
adaptors). Approximately 10% of the patients with type 1 endometrial cancer show 
gene defects promoting carcinogenesis; one representative example is hereditary 
non-polyposis colon cancer (HNPCC), known as Lynch syndrome [129] when the 
lifetime risk for endometrial cancer is 40–60% [130].
miRNAs are short (19–25 nucleotides) naturally-occurring, non-coding RNA 
molecules that base-pair with the 3′ untranslated region of target miRNAs. miRNAs 
have emerged as key regulators of gene expression, a single miRNA can target 
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and potentially silence several hundred genes, and their involvement in aging by 
modulating the presence of steroid receptors, and other molecules in endometrial 
disorders, as are EIN, and both types of endometrial cancer. Recent studies have 
identified miRNAs regulated by estrogens in human endometrial stromal cells 
[131], fact discussed because E2 levels decline in postmenopause, and are various 
age-associated disorders.
Endometrial transcriptome analysis using techniques of immnohistochemistry 
may reveal women’s risk to progesterone/progestin resistance and progression to EIN 
by measuring PRA and PRB; high expression of PRA and PRB suggesting decreased 
risk of persistence/progression to EIN, and the decrease of PRB is strongly associated 
to progression to EIN. No association was found with PTEN, and PTEN mutations, 
Pax-2, and Bcl-2, insulin like-growth factor II, with complex hyperplasia [132].
4.  Conclusions: future perspectives for middle aged women treated for 
perimenopausal symptoms
The discussed non-oral routes of MHT, meaning the transdermal/percutaneous 
route for estrogens, the vaginal route for micronized progesterone, and intrauterine 
system for proges-terone/progestogen are an update safe option for women with 
intact uterus, when the recommendation for MHT is during the “window of oppor-
tunity”. The technology of obtaining these drugs/system will help medical staff and 
middle aged women to have a better quality of life, and less morbidity and mortal-
ity. The risk of endometrial proliferative lesions as hyperplasia and carcinoma is 
reduced in comparison to non-user women, and their prognosis is better compara-
tive to non-users regarding tumor aggression and women’s survival. Endometrial 
transcriptome and new biomarkers highlight priority areas for future research, such 
as increasing the diagnostic reproductibility of endometrial hyperplasia-benign, 
and EIN and to improve the discrimination between EIN and carcinoma, and 
identifying new biomarkers to stratify risks or serve as indicators of response to 
clinical treatment.
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